David Owens - Feb 26, 2025 Form 4 Insider Report for Nexalin Technology, Inc. (NXL)

Role
Chief Medical Officer, Director
Signature
/s/ David Owens Name: David Owens, M.D.
Stock symbol
NXL
Transactions as of
Feb 26, 2025
Transactions value $
$0
Form type
4
Date filed
2/27/2025, 04:33 PM
Previous filing
Feb 5, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NXL Stock Option (right to buy) Award $0 +140K $0.00 140K Feb 26, 2025 Common Stock 140K $0.89 Direct
transaction NXL Stock Option (right to buy) Award $0 +654K +468% $0.00 794K Feb 26, 2025 Common Stock 654K $0.89 Direct F1
transaction NXL Stock Option (right to buy) Award $0 +125K +15.74% $0.00 919K Feb 26, 2025 Common Stock 125K $2.95 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in three equal annual installments based on the satisfaction of certain performance criteria for each of the annual periods ending June 30, 2024, 2025 and 2026. The performance criteria for the period ending June 30, 2024 were met, resulting in the vesting of options to purchase 218,121 shares.